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Background: Simian immunodeficiency virus (SIV) infection of nonhuman primates is the predominant model for
preclinical evaluation of human immunodeficiency virus (HIV) vaccines. These studies frequently utilize high-doses
of SIV that ensure infection after a single challenge but do not recapitulate critical facets of sexual HIV transmission.
Investigators are increasingly using low-dose challenges in which animals are challenged once every week or every
two weeks in order to better replicate sexual HIV transmission. Using this protocol, some animals require over ten
challenges before SIV infection is detectable, potentially inducing localized immunity. Moreover, the lack of certainty
over which challenge will lead to productive infection prevents tissue sampling immediately surrounding the time
of infection.
Findings: Here we challenged Mauritian cynomolgus macaques with 100 50% tissue culture infectious doses
(TCID50) of SIVmac239 intrarectally three times a day for three consecutive days. Ten of twelve animals had positive
plasma viral loads after this challenge regimen.
Conclusions: This approach represents a straightforward advance in SIV challenge protocols that may avoid
induction of local immunity, avoid inconsistent timing between last immunization and infection, and allow
sampling immediately after infection using low-dose challenge protocols.Findings
Developing both cures and vaccines for HIV requires a
clear understanding of early events after infection when
HIV seeds the latent reservoir and decimates the muco-
sal immune system; however, it is nearly impossible to
determine, with certainty, the sequence of the infecting
virus or exactly when an individual was infected. These
complications mean it is difficult to study early events
after infection or understand how the virus evolves in
response to immune pressure during early infection.
Simian immunodeficiency virus (SIV) infection of non-
human primates (NHPs) is a well-established model of
HIV [1]. NHPs enable preclinical studies of the safety* Correspondence: dhoconno@wisc.edu
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unless otherwise stated.and efficacy of HIV vaccines or therapeutic HIV inter-
ventions. Thus, SIV studies in NHPs allow for prospect-
ive experiments with well-characterized virus stocks,
invasive sampling, and known times of infection.
Until recently, investigators used extremely high-dose
challenges that did not recapitulate certain facets of sex-
ual HIV transmission. HIV infection is typically initiated
by a single virus that replicates in the tissues and then
spreads systemically [2,3]. Moreover, productive infec-
tion is a rare event; it is estimated that people are in-
fected in only approximately 1 of every 500 heterosexual
contacts [4]. When macaques are challenged with large
amounts of virus at mucosal tissues, multiple viruses ini-
tiate infection [3]. Such high-dose challenges could mask
the protective effects of an otherwise efficacious vaccine
[5]. More recently, investigators have developed a low-
dose challenge model in which macaques are repeatedly
challenged with a low-dose of SIV [3,6]. The protocols
are designed so that multiple challenges (typically threeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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vaccinated macaques. Consequently, these challenges can
take multiple weeks before all animals are productively in-
fected. While SIV transmission from low-dose challenge
protocols more closely models heterosexual HIV trans-
mission, these approaches have several drawbacks. It is
impossible to know in advance which challenge will initi-
ate productive infection, precluding studies that require
exact timing of infection or tissue sampling in the hours
or days after infection. Additionally, repeated exposures to
HIV can lead to the development of HIV-specific local and
systemic immunity [7]. It is therefore likely that similar
immune effects could occur over time in macaques ex-
posed to SIV but not productively infected. In macaque
vaccine trials using typical low-dose challenge protocols, it
may be difficult to tease apart vaccine-induced immune
responses from immune responses resulting from repeated
exposures to SIV. Certain studies may benefit from avoid-
ing this potential induction of immunity while other stud-
ies might seek to replicate it.
Our lab also performs adoptive transfers between ma-
caques to examine protective immune responses; how-
ever, the limited persistence of donor cells provides a
narrow window for SIV challenges in order to assess the
protective capacity of the transferred cells [8-10]. We
were concerned a high-dose challenge might mask anti-
viral effects exerted by the adoptively transferred cells.
The clearance kinetics of our donor cells led us to in-
vestigate whether a low-dose challenge was feasible in a
shorter timeframe. Passive antibody transfer studies
might suffer from similar issues. For example, passively
transferred neutralizing antibodies may have a short
half-life in vivo and thus a short window of potential ac-
tivity [11,12]. Therefore, we developed a protocol to
challenge animals intrarectally with a low-dose of SIV
multiple times in a short duration, an approach termed
“rapid, repeated, low-dose” infection (RRLD). All ani-
mals included in these studies were Mauritian origin cy-
nomolgus macaques and these studies were approved
by the Institutional Animal Care and Use Committee.
First, we titrated a stock of SIV in nine animals. These
animals were challenged in groups of three using 1000
TCID50, 500 TCID50, or 100 TCID50 (Figure 1). Animals
were challenged every two weeks during this titration. The
animals challenged with 1000 TCID50 were all infected
after a single challenge. The 500 TCID50 dose infected two
animals after a single challenge and one animal after two
challenges. The 100 TCID50 challenge infected one animal
with a single challenge, one animal after two challenges,
and one animal after four challenges. All animals were
monitored for 24 weeks. Two animals that share the M7
MHC haplotype maintained control of viral replication to
undetectable levels. Given the results of the titration, we
used 100 TCID50 for our low-dose challenges.The RRLD challenges were piloted in two MHC-defined
Mauritian cynomolgus macaques. Both animals were chal-
lenged with 100 TCID50 SIVmac239 intrarectally at four-
hour intervals, three times a day for three consecutive
days (Figure 2). Specifically, we delivered virus to the
WNPRC at 0700, 1100, and 1500. Virus was introduced
by a 1 ml syringe to the rectum and animals remained ele-
vated to allow for virus interaction with host cells. Chal-
lenges were typically performed on Tuesday, Wednesday,
and Thursday. These animals were lightly anesthetized at
each challenge. The animals were anesthetized for at least
10 minutes after drug delivery and allowed to recover
quickly after the procedure was finished to provide for
adequate food intake during the challenge interval. An-
imals were anesthesized with a ketamine/dexmedeto-
midine mixture with an atipamezole reversal. We used
3 mg/kg ketamine and 0.015 mg/kg dexmedetomidine
given intramuscularly (IM). This differed from the standard
dose of 5 mg/kg ketamine and 0.015 mg/kg dexmedetomi-
dine. At the end of the procedure 0.15 mg/kg atipamezole
was given IM as a reversal for the dexmedetomidine.
Supplemental food was also provided between multiple
anesthetic events, and food intake/weight were moni-
tored closely by WNPRC veterinary staff. Most animals
responded well to the lower dose of ketamine. They
remained anesthetized for the entire procedure and re-
covered quickly following the atipamezole reversal. Ani-
mals that were not sufficiently anesthetized at the
starting dose were given a higher dose of ketamine
starting at 4 mg/kg to the standard dose of 5 mg/kg.
We monitored the animals for 24 weeks after infec-
tion. We arbitrarily established the second day of chal-
lenges as day 0. Animals developed normal acute phase
viral loads that reached 3.3 × 107 and 6.9 × 106 copies
vRNA/ml plasma (Figure 3a). These viral loads are com-
parable to Mauritian cynomolgus macaques challenged
with SIV with a single high-dose of SIV (Figure 1 and
Data not shown).
Next we challenged 10 animals as part of an adoptive
transfer study (Additional file 1: Figure S1). These animals
were recipients of cells from either SIVmac239Δnef vacci-
nated or mock-vaccinated donors. A day after transfer, we
began challenging animals with SIVmac239 using the
RRLD challenge protocol. The aim of this study was to de-
termine whether cells transferred from vaccinated ma-
caques could prevent infection or reduce viral loads after
challenge. Eight of the ten animals were infected after one
round (nine total challenges in three days) of RRLD chal-
lenges (Figure 3b). One animal, cy0418, was infected with
SIVmac239Δnef as a result of the transfer but did not get
infected by SIVmac239, as determined by discriminating
qPCR (Additional file 2: Figure S2). These animals devel-
oped comparable viral loads to historic controls chal-
lenged with higher doses of SIV (Figure 3c,d). In addition,























Figure 1 Plasma vRNA per ml of plasma in animals challenged with indicated dose of SIV.
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ceived cells from vaccinated donors (Figure 2 and Data
not shown). At 24 weeks post-infection, animals that re-
ceived cells from mock-vaccinated donors exhibited re-
duced viral loads compared to the animals that received
cells from vaccinated macaques. This may be an effect of
the adoptive transfer; however, all of these animals were
enriched for the M1 MHC haplotype that is correlated
with SIV control [13]. Thus, these viral load differences
may reflect coincidental enrichment for controllers in the
animals that received cells from mock-vaccinated donor
animals. It is possible that adoptive transfer may have led
to immune activation and increased target cell susceptibil-
ity to infection; however, we do not have direct evidence
that this occurred and both pilot animals were infected
after a single round of challenges during the pilot study.
Previous studies of low-dose challenges have demon-
strated a bottleneck in the number of transmitted variants
compared to high-dose challenges [14]. We challenged
with a clonal SIVmac239 stock; however, even a clonal
stock may contain very low frequency variants [15].
Therefore, we expected that low-frequency variants might
still be detectable in animals post-challenge and that these
variants might help determine the number of transmitted
viruses. We acquired full-length SIV sequences from four
of the 12 macaques at one and two weeks post-infectionFigure 2 Rapid repeated low-dose challenge protocol. Animals were cby MiSeq. We examined 5 sets of 50,000 reads subsam-
pled from each macaque’s total reads and looked for syn-
onymous or non-synonymous SNPs present in greater
than 1% of sequence reads in at least three of the sub-
sampled alignments. All animals had at least one SNP at
one week post-infection and cy0571 had 19 SNPs (data
not shown). The large number of SNPs detected in cy0571
may reflect re-sequencing artifacts because cy0571 had
plasma viral loads below 1000 copies vRNA/ml plasma.
The majority of the variants in cy0571 were undetect-
able by 2 weeks post-infection while other animals ex-
hibited similar numbers of SNPs at one and two weeks
post-infection. The contraction in viral genetic diversity
in cy0571 suggests that sequencing virus at time-points
after one-week post-infection may underestimate diver-
sity of the viruses that initiate and seed infection. We
compared the number of SNPs detected in the RRLD
animals to two animals challenged with 7,000 TCID50.
We did not detect differences between the number of
SNPs in animals challenged with a high-dose or low-
dose of SIV at one week post-infection; however, there
were limited number of animals in this control group.
These results demonstrate that it is possible to con-
dense low-dose challenge regimens into a three-day win-
dow. In the current approach, the specific challenge(s)

















































































































Figure 3 Viral loads were measured in SIV-challenged animals. Plasma vRNA per ml of plasma. a) in two pilot animals challenged by RRLD
and b) in ten animals that received cells from donor macaques and were then challenged using the RRLD protocol. These ten animals include
both vaccinated animal cell recipients (VACR) and mock-vaccinated animal cell recipients (MVACR). c) Peak viral loads for animals challenged by
RRLD protocol or standard single 50,000 TCID50 challenge. d) Viral loads from RRLD and standard single 50,000 TCID50 challenge at 16-18 weeks
postinfection. The high-dose challenge viral loads have been published in a previous manuscript [10].
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in productive infection can utilize distinctly barcoded
viruses [16]. Using a uniquely barcoded virus in each
challenge should allow for a clear delineation of which
challenge or challenges infected the animals. We expect
that these results could be extrapolated to other models
of HIV infection including the more pathogenic infec-
tion of rhesus macaques; however, labs would likely
need to titrate their stocks prior to beginning theirexperiments. Ultimately, these studies demonstrate that
it should be possible to proceed more rapidly through
low-dose challenge regimens.
We foresee several circumstances in which this novel
challenge protocol may be valuable. First, investigators
are performing in situ studies of animal tissue shortly
after challenge when SIV is replicating in the tissues;
however, these studies require that animals be euthanized
after challenge and necessitate high-dose challenges to
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after infection [17-19]. By rapidly performing multiple
challenges, investigators can be relatively confident that an
animal was productively infected; thus, they can perform
invasive sampling or euthanize an animal and study early
acute events while using a low-dose challenge.
Second, investigators performing microbicide and vac-
cine trials are frequently interested in studying the longi-
tudinal efficacy of the relevant intervention. Currently,
low-dose challenge protocols yield indeterminate inter-
vals between microbicide application or vaccination and
infection because animals may need to be challenged
on multiple occasions spanning several weeks or months.
The RRLD protocol provides a much more clearly defined
duration between intervention and challenge.
Finally, the RRLD protocol could be adapted to use
ultra-low-dose challenges. As discussed above, HIV trans-
mission is rare, with only 1 in 500 heterosexual contacts
leading to HIV infection [4]. Low-dose challenges more
accurately duplicate the biology of HIV transmission be-
cause, typically, only one virus leads to systemic infection,
but current low-dose challenges still result in infection at
a far higher rate than is actually observed in humans. It is
conceivable that these low-dose challenges are too strin-
gent, and may mask the protective efficacy of vaccines in
pre-clinical trials. It should be possible to further titrate
the virus challenge stock until only 1 in every 100 chal-
lenges results in a productive infection. Animals could be
challenged with an ultra-low-dose of SIV by RRLD proto-
col for 9-10 weeks until all animals are infected. For ex-
ample, animals could be challenged, 9 times over three
days and similarly re-challenged every 2-3 weeks. Using
this rapid, repeated, ultra-low-dose protocol, the number of
challenges to infect animals is an additional, measureable
parameter of vaccine efficacy. This regimen would reintro-
duce elements of traditional low dose challenges like poten-
tial immune induction from repeated SIV exposures, but
might provide a valuable model of HIV infection. It would
also require a large number of anesthetic events, but ani-
mals are lightly anesthetized for these procedures and the
challenges could be performed over a longer period of time.
Ultimately, the RRLD regimen may more accurately recap-
itulate sexual HIV transmission than a single high-dose
challenge while allowing for more intensive sampling dur-
ing the very early stages of viral replication and known du-
rations between intervention and infection. Certain studies
may benefit from this novel challenge protocol.
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